Abstract
The occurrence of autoantibodies is a common feature of autoimmune diseases. This review is intended to give an overview of the most important autoantibodies and their role in diagnosis, disease activity and prognosis in rheumatoid arthritis (RA), systemic lupus erythematodes (SLE) and multiple sclerosis (MS). Whereas in RA and SLE these antibodies are meaningful for diagnosis and partially for the prognosis of the disease, the situation is quite different in the case of MS. Up to date, no specific antibody is known to be exclusively present in the serum or cerebrospinal fluid (CSF) of MS-patients compared to the respective fluids of healthy individuals. Nevertheless, there are some antigens that are reported to be bound significantly more often by MS-patients serum or CSF than by comparable samples of healthy volunteers. In addition to the importance of several autoantibodies for diagnosis of the respective disease, the serum concentration of certain antibodies in RA and SLE is associated with therapy response. Since therapy with biologicals (e.g. TNF- αblockade, B-cell depletion) is expensive, monitoring these autoantibodies seems to be an additional useful tool for early identification of therapy responders or non-responders.
Keywords: Autoantibodies, rheumatoid arthritis, systemic lupus erythematodes, diagnosis, prognosis, therapy
Current Pharmaceutical Design
Title: Autoantibodies in Autoimmune Diseases
Volume: 16 Issue: 14
Author(s): M. Eggert, U. K. Zettl and G. Neeck
Affiliation:
Keywords: Autoantibodies, rheumatoid arthritis, systemic lupus erythematodes, diagnosis, prognosis, therapy
Abstract: The occurrence of autoantibodies is a common feature of autoimmune diseases. This review is intended to give an overview of the most important autoantibodies and their role in diagnosis, disease activity and prognosis in rheumatoid arthritis (RA), systemic lupus erythematodes (SLE) and multiple sclerosis (MS). Whereas in RA and SLE these antibodies are meaningful for diagnosis and partially for the prognosis of the disease, the situation is quite different in the case of MS. Up to date, no specific antibody is known to be exclusively present in the serum or cerebrospinal fluid (CSF) of MS-patients compared to the respective fluids of healthy individuals. Nevertheless, there are some antigens that are reported to be bound significantly more often by MS-patients serum or CSF than by comparable samples of healthy volunteers. In addition to the importance of several autoantibodies for diagnosis of the respective disease, the serum concentration of certain antibodies in RA and SLE is associated with therapy response. Since therapy with biologicals (e.g. TNF- αblockade, B-cell depletion) is expensive, monitoring these autoantibodies seems to be an additional useful tool for early identification of therapy responders or non-responders.
Export Options
About this article
Cite this article as:
Eggert M., Zettl U. K. and Neeck G., Autoantibodies in Autoimmune Diseases, Current Pharmaceutical Design 2010; 16 (14) . https://dx.doi.org/10.2174/138161210791164144
DOI https://dx.doi.org/10.2174/138161210791164144 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Forward Path for Biopharmaceuticals and Biosimilars: Emerging Options in the Selection of Host Cell Systems
Current Biotechnology The Clinical Spectrum, Diagnosis, Pathogenesis and Treatment of Hashimotos Encephalopathy (Recurrent Acute Disseminated Encephalomyelitis)
Current Medicinal Chemistry The Role of Macrophages in Rheumatoid Arthritis
Current Pharmaceutical Design Association Study of IL-4 -590 C/T and DDX39B -22 G/C Polymorphisms with the Risk of Late-Onset Alzheimer’s Disease in Iranian Population
Current Aging Science Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Achievements and Challenges of Proteomics in the Study of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Hypusine Modification of the Ribosome-binding Protein eIF5A, a Target for New Anti-Inflammatory Drugs: Understanding the Action of the Inhibitor GC7 on a Murine Macrophage Cell Line
Current Pharmaceutical Design Chalcones in Cancer: Understanding their Role in Terms of QSAR
Current Medicinal Chemistry Inflammation in Peripheral Arterial Disease (PAD)
Current Pharmaceutical Design Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery A Validation and Estimation of Total Eicosapentaenoic and Docosahexaenoic acids Using LC-MS/MS with Rapid Hydrolysis Enzymatic Method for Hydrolysis of Omega Lipids in Human Plasma and its Application in the Pharmacokinetic Study
Current Pharmaceutical Analysis Src Inhibitors and Angiogenesis
Current Pharmaceutical Design QbD-Enabled Systematic Development of Ileo-Colonic Targeted Novel Mucoadhesive Microspheres of Flurbiprofen
Current Drug Delivery Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Pharmaceutical and Biomedical Applications of Interpenetrating Polymer Network
Current Drug Therapy The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-Interleukin-6 Receptor Antibody Treatment in Inflammatory Autoimmune Diseases
Reviews on Recent Clinical Trials Editorial: Teratology and Reproductive Toxicology of Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry